Hamostaseologie最新文献_第8页

Oral Anticoagulation and Mortality in Cases with Intracranial Bleeding: Analysis of Nationwide Prescription and Hospitalization Data. 口服抗凝药与颅内出血病例的死亡率：全国处方和住院数据分析》。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-05 DOI: 10.1055/a-2229-8047

Knut Kröger, Fabian Heldt, Ludger Feyen, Kathrin Feller, Bernd Kowall, Andreas Stang

{"title":"Oral Anticoagulation and Mortality in Cases with Intracranial Bleeding: Analysis of Nationwide Prescription and Hospitalization Data.","authors":"Knut Kröger, Fabian Heldt, Ludger Feyen, Kathrin Feller, Bernd Kowall, Andreas Stang","doi":"10.1055/a-2229-8047","DOIUrl":"https://doi.org/10.1055/a-2229-8047","url":null,"abstract":"Objectives: To demonstrate the safety of direct oral anticoagulants in relation to intracranial bleeding (ICB), we compared the number of patients taking anticoagulants in all cases of hospitalization and cases of hospitalization for ICB over time in Germany. We analyzed the intrahospital mortality of ICB cases in relation to long-term use of anticoagulants (LUAs).We performed a retrospective registry analysis of nationwide German hospitalizations including all hospital admissions and admission for ICB in patients aged ≥60 years in the period from 2006 to 2020 and separated for LUAs.Results: In 2006, the age-standardized rate of hospitalized male patients with LUAs was 7.3% and that of female patients was 5.6%. In 2020, the rates increased to 22.0 and 17.7% for male and female patients, respectively. Among patients hospitalized for ICB in 2006, 7.0 and 5.6% were male and female patients with LUAs, respectively. In 2020, the rate increased to 13.7% for males and 10.8% for females.In 2006, age-standardized mortality rates of male and female patients with ICB without LUAs were 24.1 and 23.9%, respectively. In 2020, the rate slightly decreased to 22.7% in males, but it remained almost unchanged in females at 23.8%. In the cases with LUA, the mortality rate decreased from 30.1 to 24.3% in males and from 28.4 to 24.2% in females in the same period.Conclusion: LUA seems to be safe because there is a slower increase of the rate of LUAs in ICB cases than in generally hospitalized cases in the period from 2006 to 2020. In addition, mortality in ICB cases with LUA tends to decrease compared to cases without LUA.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Petition "Vergütung für medizinische Leistungen - Verbesserung der Rahmenbedingungen für die ambulante Versorgung", ATMP-QS-Richtlinie Hämophilie und aktueller Stand zur Digitalisierung im Gesundheitswesen: E-Rezept. 请愿书 "医疗服务报酬--改善门诊护理的框架条件"、ATMP-QS 血友病指南和医疗保健行业的数字化现状：电子处方。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2177-9429

Jürgen Koscielny, Günther Kappert, Christoph Sucker

引用次数: 0

Thrombozytopenie: Sind Thrombozytentransfusionen vor Legen eines ZVK verzichtbar? 血小板减少症：置入 CVC 前是否可以不输血小板？

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/s-0044-1782594

引用次数: 0

Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management. 重塑抗凝：血栓管理中的因子 XI 抑制。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2023-12-20 DOI: 10.1055/a-2202-8620

Andreas Verstraete, Matthias M Engelen, Charlotte Van Edom, Thomas Vanassche, Peter Verhamme

引用次数: 0

Pathophysiology of Trauma-Induced Coagulopathy. 创伤诱发凝血病的病理生理学。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2215-8936

Herbert Schöchl, Felix C F Schmitt, Marc Maegele

{"title":"Pathophysiology of Trauma-Induced Coagulopathy.","authors":"Herbert Schöchl, Felix C F Schmitt, Marc Maegele","doi":"10.1055/a-2215-8936","DOIUrl":"10.1055/a-2215-8936","url":null,"abstract":"Trauma-induced coagulopathy (TIC) is a complex hemostatic disturbance that can develop early after a major injury. There is no universally accepted definition of TIC. However, TIC primarily refers to the inability to achieve sufficient hemostasis in severely injured trauma patients, resulting in diffuse microvascular and life-threatening bleeding. Endogenous TIC is driven by the combination of hypovolemic shock and substantial tissue injury, resulting in endothelial damage, glycocalyx shedding, upregulated fibrinolysis, fibrinogen depletion, altered thrombin generation, and platelet dysfunction. Exogenous factors such as hypothermia, acidosis, hypokalemia, and dilution due to crystalloid and colloid fluid administration can further exacerbate TIC. Established TIC upon emergency room admission is a prognostic indicator and is strongly associated with poor outcomes. It has been shown that patients with TIC are prone to higher bleeding tendencies, increased requirements for allogeneic blood transfusion, higher complication rates such as multi-organ failure, and an almost fourfold increase in mortality. Thus, early recognition and individualized treatment of TIC is a cornerstone of initial trauma care. However, patients who survive the initial insult switch from hypocoagulability to hypercoagulability, also termed \"late TIC,\" with a high risk of developing thromboembolic complications.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 1","pages":"31-39"},"PeriodicalIF":3.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GTH 2024: Building Bridges in Coagulation. GTH 2024：搭建凝血的桥梁

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/s-0044-1779290

Cihan Ay, Christoph Male

引用次数: 0

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies. 癌症患者血栓风险的最新情况：关注新型抗癌免疫疗法。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2215-9909

Florian Moik, Jakob M Riedl, Cornelia Englisch, Cihan Ay

{"title":"Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies.","authors":"Florian Moik, Jakob M Riedl, Cornelia Englisch, Cihan Ay","doi":"10.1055/a-2215-9909","DOIUrl":"10.1055/a-2215-9909","url":null,"abstract":"Thromboembolic complications, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), increase mortality and morbidity, and delay treatment in patients with cancer. Therefore, an increased understanding of underlying risk profiles, the identification of risk factors and predictive biomarkers, and ultimately the development of specific cardiovascular prevention strategies in patients with cancer is needed. Medical anticancer therapies have undergone a remarkable development in recent years with the advent of targeted and immunotherapeutic treatment options, including immune checkpoint inhibitors (ICI), chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers (BiTEs). These developments have important implications for the accompanied risk of thromboembolic events in patients with cancer. First, the increased use of these highly effective therapies renders a growing proportion of patients with cancer at risk of thromboembolic events for a prolonged risk period due to an increase in patient survival despite advanced cancer stages. Second, potential direct cardiovascular toxicity and prothrombotic effect of novel anticancer immunotherapies are a matter of ongoing debate, with emerging reports suggesting a relevant risk of VTE and ATE associated with ICI, and relevant dysregulations of hemostasis in the frequently observed cytokine-release syndrome associated with BiTEs and CAR T-cell therapy. The aim of the present narrative review is to summarize the implications of the emerging use of anticancer immunotherapy for thromboembolic events in patients with cancer, and to provide an overview of available data on the rates and risk factors for VTE and ATE associated with ICI, CAR T-cell therapy, and BiTEs.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"40-48"},"PeriodicalIF":3.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life. 血栓性血小板减少性紫癜 100 年：死亡与生命的故事》。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2223-9484

Bernhard Lämmle, Karen Vanhoorelbeke, Johanna A Kremer Hovinga, Paul Knöbl

引用次数: 0

Clonal Hematopoiesis and Cardiovascular Risk: Atherosclerosis, Thrombosis, and beyond. 克隆性造血与心血管风险：动脉粥样硬化、血栓形成及其他。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2219-6410

Benedetta Izzi, José J Fuster

引用次数: 0

Vakzin-induzierte Immunthrombozytopenie und Thrombose: Langfristiger Outcome. 疫苗引起的免疫性血小板减少症和血栓形成：长期结果